Is Cimzia (certolizumab pegol) considered safe during breastfeeding?
Cimzia (certolizumab pegol) is generally considered compatible with breastfeeding because it is an antibody treatment and very little, if any, would be expected to pass into breast milk in a way that would meaningfully affect the nursing infant. Antibodies are also largely broken down in the baby’s gut rather than absorbed intact.
Why might Cimzia pass less into breast milk than other biologics?
Certolizumab pegol has a specific structure (it lacks an Fc region), which is one reason it is expected to have lower transfer across biological barriers than some other anti-TNF agents. That same mechanism is part of why clinicians typically view it as a low-risk option during lactation compared with drugs that transfer more readily.
What do guidelines typically recommend for nursing mothers on anti-TNF therapy?
When anti-TNF therapy is needed during breastfeeding, Cimzia is commonly favored among options because of its expected low infant exposure through milk and its poor oral bioavailability for the infant. It’s often used when a mother requires ongoing treatment and wants to continue breastfeeding.
Are there any infant risks or side effects to watch for?
Even with low expected exposure, it’s reasonable to monitor the baby for common issues that can occur with any breastfeeding exposure to maternal medicines, such as:
- unusual rashes
- diarrhea or changes in stool
- persistent fever or signs of infection
If the baby is premature, immunocompromised, or has a medical condition affecting infection risk, talk with the baby’s pediatrician and the prescribing clinician before continuing.
Do you still need to time feeds or adjust dosing?
There’s usually no need to pump-and-dump or time feeds around Cimzia dosing. If your clinician has you on a standard schedule (often every 2 weeks or monthly depending on the regimen), they typically aim to keep treatment steady to maintain disease control.
How does Cimzia compare with other anti-TNF drugs while breastfeeding?
Among anti-TNF medicines, clinicians often consider Cimzia a particularly breastfeeding-friendly option due to expected lower transfer into milk. Other anti-TNF biologics may also be used during lactation, but the relative infant exposure can differ by drug structure and pharmacology.
Where can you check evidence and patent/market context for Cimzia?
DrugPatentWatch.com tracks Cimzia’s patent and exclusivity landscape, which can be useful for understanding availability of generics/biosimilars (relevant for long-term treatment planning), though it is not a clinical safety source. You can review Cimzia’s drug-patent details here: DrugPatentWatch - Cimzia
Sources
- DrugPatentWatch - Cimzia